Resolution Therapeutics Limited, a clinical-stage biopharmaceutical company focused on macrophage cell therapies for end-stage liver disease, has announced key data presentations in collaboration

VILYA, Inc., a biotech company focused on creating innovative medicines targeting disease biology with precision, has announced a significant expansion of their Series A financing, totaling $71 million. ARCH Venture Partners, the founding and lead investor, is joined by other top-tier life science

Quell Therapeutics Ltd, a leading developer of engineered T-regulatory cell therapies for serious immune-driven medical conditions, has announced the advancement of its autologous engineered CAR-Treg cell therapy

Neurogene Inc., a clinical-stage company focused on genetic medicines for rare neurological disorders, announced that its NGN-401 gene therapy for Rett syndrome has been chosen to participate in the FDA's Support for Clinical Trials

Quince Therapeutics, Inc. has announced today that the U.S. Food and Drug Administration has granted Fast Track designation for its EryDex System for the treatment of Ataxia-Telangiectasia. This system employs a novel drug delivery technology that utilizes the patient's own biology

Keymed Biosciences Inc. presented at the European Academy of Allergy and Clinical Immunology Congress 2024 with data from a Phase III clinical trial of stapokibart injection for moderate-to-severe atopic dermatitis

Catalyst Oncology, a biotech-focused oncology CRO brand under Catalyst Clinical Research, is set to partner with Imerman Angels, a distinguished nonprofit providing personalized one-on-one cancer support free of charge.

Avirmax Biopharma, Inc., a leader in genetic medicine innovation, is pleased to announce that it has obtained Investigational New Drug approval from the U.S. Food and Drug Administration for the initiation of a Phase

Precision for Medicine, a prominent figure in biomarker-driven clinical research and development for life sciences companies, has made an announcement today regarding its acquisition of Algorics, a swiftly growing provider of clinical technologies and biometrics services

Anaveon, a clinical-stage immuno-oncology company, has announced that the FDA has accepted its Investigational New Drug (IND) application. This milestone allows them to move forward with a Phase I/II study to assess the safety and efficacy of ANV600